The contribution of ketone bodies to glycolytic inhibition for the treatment of adult and pediatric glioblastoma.

Targeting the metabolic pathway of GBM via glycolytic inhibition in conjunction with ketogenic diet or exogenous ketone body supplementation warrants further investigation as a promising adjunctive treatment to conventional therapy.